Germline Pathogenic Variants and Clinical Outcomes in Asian Patients With Breast Cancer
Cancer Science · 2025
DOI: 10.1111/cas.70002 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2025. Verfasst von Rui Kitadai und 38 weiteren Autor:innen. Beteiligte Einrichtung: Division of Genome Biology, National Cancer Center Research Institute, Tokyo, Japan. Hauptthemen laut MEDLINE: Breast Neoplasms, Germ-Line Mutation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Health Labour Sciences Research Grant, Japan Society for the Promotion of Science, Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
Despite the importance of genetic testing for risk assessment and treatment in breast cancer, the prognostic impact of germline pathogenic variants (PVs), especially in Asian populations, is unclear. We assessed the impact of germline PVs in patients with early‐stage breast cancer. This study included 7278 Japanese multihospital registry patients. PVs of ATM , BRCA1 , BRCA2 , CDH1 , CHEK2 , NBN , NF1 , PALB2 , PTEN , STK11 , and TP53 were evaluated. PV and non‐PV carriers were matched by age, histology, and stage. Associations between PVs and survival were assessed. The primary outcome was invasive disease‐free survival (IDFS). Secondary outcomes included relapse‐free survival (RFS), overall survival, and breast cancer‐specific survival. We identified 320 (4.4%) patients with BRCA1/2 PVs and 79 (1.1%) with PVs other than BRCA1/2 (non‐ BRCA1/2 ). A total of 360 patients ( BRCA1/2 , n = 289; non‐ BRCA1/2 , n = 71) were matched to 720 noncarriers. Patients with BRCA1/2 PVs had significantly shorter 10‐year IDFS (adjusted hazard ratio (aHR) = 2.15; 95% confidence interval (CI), 1.61–2.86; p < 0.001); and RFS (aHR = 1.74; 95% CI, 1.25–2.44; p = 0.001) than noncarriers. Among patients with hormone receptor‐positive HER2‐negative breast cancer, BRCA1/2 PV carriers exhibited significantly shorter 10‐year IDFS than noncarriers, even those with stage I/II disease (total, aHR = 2.23; 95% CI, 1.55–3.23; p < 0.001, Stage I/II, aHR = 2.22; 95% CI, 1.43–3.44; p < 0.001). There was no significant difference in 10‐year IDFS between the non‐ BRCA1/2 PV carrier and noncarrier groups (aHR = 1.40; 95% CI, 0.67–2.93; p = 0.37). Asian patients with breast cancer carrying germline BRCA1/2 PV, even those with a low recurrence risk, have significantly shorter 10‐year IDFS than noncarriers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Genome Biology, National Cancer Center Research Institute, Tokyo, Japan.
- Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
- Department of International Clinical Development, National Cancer Center Hospital, Tokyo, Japan.
- Teikyo University Graduate School of Public Health, Tokyo, Japan.
- Biostatistics Division, Center for Research Administration and Support/Division of Biostatistical Research, Institute for Cancer Control, National Cancer Center, Tokyo, Japan.
- Department of Breast Surgery and Oncology, Kanagawa Cancer Center, Yokohama, Japan.
ORCID-Profile: Rui Kitadai, Shu Yazaki, Yosuke Hirotsu, Ryuji Hamamoto, Akihiko Shimomura, Kazuki Sudo, Kuniko Sunami, Hiroshi Nakagomi, Yoichi Naito, Kan Yonemori, Takashi Kohno, Kouya Shiraishi
Förderung
- Health Labour Sciences Research Grant
- Japan Society for the Promotion of Science
- Japan Agency for Medical Research and Development
Zitieren
APA
Kitadai, R., Yazaki, S., Kuchiba, A., Yamanaka, T., Shiino, S., Yamauchi, C., Harano, K., Saito, M., Hirotsu, Y., Aiba, H., Yoshida, T., Hamamoto, R., Shimizu, C., Shimomura, A., Kojima, Y., Shimoi, T., Momozawa, Y., Sudo, K., Yoshida, M., …, & Shiraishi, K. (2025). Germline Pathogenic Variants and Clinical Outcomes in Asian Patients With Breast Cancer. Cancer Science. https://doi.org/10.1111/cas.70002
Vancouver
Kitadai R, Yazaki S, Kuchiba A, Yamanaka T, Shiino S, Yamauchi C, et al. Germline Pathogenic Variants and Clinical Outcomes in Asian Patients With Breast Cancer. Cancer Science. 2025. doi:10.1111/cas.70002
BibTeX
@article{Kitadai2025,
author = {Kitadai, Rui and Yazaki, Shu and Kuchiba, Aya and Yamanaka, Takashi and Shiino, Sho and Yamauchi, Chisako and Harano, Kenichi and Saito, Motonobu and Hirotsu, Yosuke and Aiba, Hisaki and Yoshida, Teruhiko and Hamamoto, Ryuji and Shimizu, Chikako and Shimomura, Akihiko and Kojima, Yuki and Shimoi, Tatsunori and Momozawa, Yukihide and Sudo, Kazuki and Yoshida, Masayuki and Sunami, Kuniko and Hori, Megumi and Katanoda, Kota and Shimada, Yoko and Yamashita, Yuji and Kogawa, Takahiro and Murata, Takeshi and Fujiwara, Saori and Miyagi, Yohei and Nakagomi, Hiroshi and Tachibana, Kazunoshin and Omata, Masao and Ohtake, Tohru and Suto, Akihiko and Onishi, Tatsuya and Naito, Yoichi and Yamashita, Toshinari and Yonemori, Kan and Kohno, Takashi and Shiraishi, Kouya},
title = {Germline Pathogenic Variants and Clinical Outcomes in Asian Patients With Breast Cancer},
journal = {Cancer Science},
year = {2025},
doi = {10.1111/cas.70002}
}
EUVIMED